FR Notice Details

Application Information
049
00Y
11/04/2024
Rahway
NJ
Merck Sharp & Dohme LLC
Completed
B-056-2024
True
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
[Federal Register Volume 89, Number 213 (Monday, November 4, 2024)]
[Notices]
[Pages 87542-87543]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-25580]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-56-2024]


Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production 
Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for 
Research and Development); Rahway, New Jersey

    Merck, Sharp & Dohme LLC submitted a notification of proposed 
production activity to the FTZ Board (the Board) for its facility in 
Rahway, New Jersey, within Subzone 49Y. The notification conforming to 
the requirements of the Board's regulations (15 CFR 400.22) was 
received on October 18, 2024.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via www.trade.gov/ftz. The proposed finished 
product(s) and material(s)/component(s) would be added to the 
production authority that the Board previously approved for the 
operation, as reflected on the Board's website.
    The proposed finished products for research and development include 
MK-2828 and MK-3214 cardiovascular disease drug products, MK-2420 
autoimmune disease drug product, MK-4646 HIV drug product, and MK-0472 
oncology drug product (duty free).
    The proposed foreign-status materials/components include MK-2828 
and MK-3214 cardiovascular disease active pharmaceutical ingredients 
(API), MK-2420 autoimmune disease API, MK-4646 HIV API, and MK-0472 
oncology API (duty rate, 6.5%). The request indicates that certain 
materials/components are subject to duties under section 301 of the 
Trade Act of 1974 (section 301), depending on the country of origin. 
The applicable section 301 decisions require subject merchandise to be 
admitted to FTZs in privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
ftz@trade.gov. The closing period for their receipt is December 16, 
2024.

[[Page 87543]]

    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Diane Finver at 
Diane.Finver@trade.gov.

    Dated: October 30, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-25580 Filed 11-1-24; 8:45 am]
BILLING CODE 3510-DS-P